Literature DB >> 34938333

An Iranian Congenital Adrenal Hypoplasia Patient with Elevated Testosterone in Infancy due to a Novel Pathogenic Frameshift Variant in NR0B1.

Samira Kalayinia1, Saeed Talebi2, Mohammad Miryounesi3, Peymaneh Sarkhail4, Nejat Mahdieh1,5.   

Abstract

X-linked congenital adrenal hypoplasia due to NR0B1 mutation is characterized by hypogonadotropic hypogonadism (HH) and infertility. Here, we describe a novel pathogenic frameshift variant in NR0B1 associated with congenital adrenal hypoplasia by whole exome sequencing in an Iranian case with high level of testosterone. Clinical evaluations and pedigree drawing were performed. Point mutations, gene conversions, and large deletions of the CYP21A2 gene were checked. WES and segregation analyses were conducted. In silico analysis was also performed for the novel variant. The ACTH, 17-hydroxy progesterone c, and DHEA sulfate values were elevated up to 624.6 pg/mL, 8.6 pmol/L, and 17.8UMOL/L, respectively. No mutation was found in the CYP21A2 gene. WES identified a novel hemizygous frameshift insertion c.218_219insACCA: p.His73GlnfsTer41 variant in the NR0B1 gene with a pathogenic effect according to ACMG criteria. Genetic testing is helpful for differential diagnosis in primary adrenal insufficiency disorders. NR0B1 may be a common cause of congenital adrenal hypoplasia in our population.
Copyright © 2021 Samira Kalayinia et al.

Entities:  

Year:  2021        PMID: 34938333      PMCID: PMC8687805          DOI: 10.1155/2021/4367028

Source DB:  PubMed          Journal:  Int J Endocrinol        ISSN: 1687-8337            Impact factor:   3.257


1. Introduction

NR0B1 mutation leads to the congenital adrenal hypoplasia (CAP) as a rare X-linked disorder with an estimated prevalence of 1 : 140,000–1 : 1,200,000 in a general population [1]. X-linked congenital adrenal hypoplasia is usually characterized by adrenal insufficiency at ages from infancy to early childhood and hypogonadotropic hypogonadism (HHG) and infertility at later ages in males [2]. This gene encodes a transcription factor named DAX1 which is a member of the nuclear receptor superfamily. It has an important role in development of the adrenal and reproductive function and axes [3, 4]. NR0B1 mutations usually result in primary adrenal insufficiency and hypogonadotropic hypogonadism; however, there are some reports of patients with elevated levels of testosterone [5, 6]. The severity of clinical characteristics including degree and onset of adrenal insufficiency due to different mutations of NR0B1 has been shown to vary in individuals with adrenal insufficiency and reproductive phenotypes [1, 7]. Mild phenotypes usually result from residual activity of the mutant protein [8]. More than two hundreds variants have been reported in the NR0B1 gene (http://www.hgmd.cf.ac.uk). About one-third of its mutations are small indels as frameshift variants. Here, we describe a novel frameshift variant in an Iranian infant with high level of testosterone.

2. Materials and Methods

2.1. Sampling and Whole Exome Sequencing

A small family with a CAH-affected son was referred to our center. The patient had been screened for all exons and intron boundaries of the CYP21A2 gene previously, and no pathogenic variants were detected. After signing the informed consent, approved by the RHC Ethics Committee, DNA was extracted from obtained blood of the family members (healthy/patient). Exome was captured by using anAgilent SureSelect Exome Capture kit (Agilent Inc., Santa Clara, California, USA). Then, the sequencing of the enriched exon libraries was performed on the Illumina HiSeq 4000 (Macrogen Inc., Seoul, South Korea).

2.2. Read Mapping, Snp/Indel Calling, and Filtering

The sequencing reads were aligned to the human genome reference (GRCh37 build) by the BWA (v07.17) tool [9]. The quality of exome data mapping to the reference genome was 98.8%, and the target region coverage was 99%. Next, snp/indel was called applying the GATK (v4.1.4.1) tool with the result file of mapping (BAM). The mark and remove duplicates were performed by SAMtools (in GATK package) [10]. Then, recalibration and snp/indel calling were performed. The confident variants were filtered and prioritized due to minor allele frequency (MAF >0.05) of 1000 genome, gnomAD (v2.1.1), and ExAc [11] databases.

2.3. PCR and Sanger Sequencing of NR0B1

The variant of the NR0B1 gene was sequenced applying the PCR and Sanger sequencing method. The primer pairs, i.e., 5´-ACTGGGCAGAACTGGGCTAC-3´ and 5´-GCGCTTGATTTGTGCTCGT-3´, were designed and validated using Primer3 (v.04.0) (http://bioinfo.ut.ee/primer3-0.4.0/) and BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome). The Sanger sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies; Thermo Fisher Scientific, Shanghai, China) on ABI Sequencer 3500XL PE (Applied Biosystems, CA, USA).

2.4. Homology Modeling and Bioinformatics Analysis

Homology modeling was used to obtain a 3D structural model of NR0B1 protein, due to the lack of crystal structure for this protein and evaluation of the mutation effect on structure and function. The NR0B1 sequence was retrieved from the UniProt database (UniProt ID: P51843). The SWISS-MODEL server (https://swissmodel.expasy.org/) [12] was applied for homology modeling. The protein FASTA sequence was submitted as an input, without assigning any restraints and templates. The SWISS-MODEL models structures of target protein and comprises conserved ligands by using BLAST and HHblits. It indicates the model quality estimation per residue based on a QMEAN score, and CAMEO monitors the accuracy of SWISS-MODEL, overlay. In addition, bioinformatics analysis was performed applying algorithms to evaluate the pathogenicity of detect variants. The prediction tools such as CADD, SIFT, Polyphen2, Provean, fathmm, and GERP++ were used. The variant that was interpreted to be pathogenic in at least 4 algorithms was considered for confirmation/segregation analysis.

3. Results

3.1. Clinical Characteristics

The patient (III-1) was 9-month-old Iranian boy from a first cousin couple. There was no history of medical problems in the pedigree (Figure 1(a)). The infant was introduced to our center at the same age 9 months, with the diagnosis of CAH for genetic testing. The patient's history since birth was as follows: he was born by cesarean section, the birth weight and length were 3.25 kg and 53 cm, respectively, and blood sugar was at a normal level since the first days of life. The hyperbilirubinemia was observed in the second day after birth, and four days of phototherapy treatment was performed. Several days after discharge, he was admitted again due to vomiting and jaundice (total bilirubin = 14 mg/dL). Electrolytes were evaluated in the first step of workup that indicated hyponatremia (sodium of 125 mmol/L), hyperkalemia (potassium of 7.5 mmol/L), and metabolic acidosis (Table 1). The medical record was significant for hyponatremia and hypokalemia. Despite the treatment with sodium chloride and fludrocortisone, hyponatremia continued. Failure to thrive, poor feeding, vomiting, and seizures have been reported for this infant; however, there were not any dysmorphic genitalia and features. The ACTH, 17-hydroxy progesterone c, and DHEA sulfate values were elevated up to 624.6 pg/mL, 8.6 pmol/L, and 17.8 UMOL/L, respectively. Our patient showed a high level of testosterone.
Figure 1

(a) Pedigree of the studied family with the patient denoted in black. (b) DNA sequence chromatograms indicate the inherited c.218_219insACCA: p.His73GlnfsTer41 variant in NR0B1, encoding the nuclear receptor subfamily 0 group B member 1.

Table 1

Biochemical analyses of the CAH patient blood

Parameters (unit)Measured values in the patientReference values [13]
SerumBlood sugar (mg/dL)81<140
Sodium (mmol/L)138135–146
Potassium (mmol/L)4.44.1–5.3

PlasmaACTH (pg/mL) 624.6 7.2–63
Renin supine (mcIU/mL)1404.2–59.7

Serum17-Hydroxy progesterone c (pmol/L) 8.6 0.2–2.9
Testosterone (ng/ml)3.10.12–0.2
DHEA sulfate (UMOL/L) 17.8 0–6.7
Androstenedione (ng/mL)0.050.08–2.5
Cortisol (µg/dL)5.33.7–19.4

3.2. Genetic Investigations

After filtering the WES data, the novel hemizygous frameshift insertion c.218_219insACCA: p.His73GlnfsTer41, in exon 1 of the NR0B1 gene, was identified which is probably responsible for CAH in this family. The c.218_219insACCA was confirmed and segregated in the studied proband as well as his mother by using PCR and Sanger sequencing. According to the segregation analysis result, CAH inherited in this family with X-linked recessive pattern (Figure 1). The best model of NR0B1 was totally designed using 3f5c.1, due to SWISS-MODEL templates library, as the first ranked template with 79% identity. This structure had a QMEAN score of −4.08 that indicates the model is more reliable with low local error score. Due to the complete destruction of NR0B1 protein resulting from p.His73GlnfsTer41 variant, no mutant structure model was obtained (Figure 2). Given American College of Medical Genetics and Genomics 2015 (ACMG) [14], the c.218_219insACCA is determined as a pathogenic variant, i.e., criteria: PVS1, PM2, PP4, PP1, and PP3. The frameshift insertion variant was supported as the cause of disease by CADD, SIFT, Polyphen2, Provean, Fathmm, and GERP++.
Figure 2

The SWISS-MODEL templates library (3f5c.1) and homology modeling of NR0B1.

4. Discussion

Primary adrenal insufficiency (PAI) is an etiologically heterogeneous group of disorders which could be potentially life threatening. As an acute onset form of PAI, X-linked congenital adrenal hypoplasia (CAP) is characterized by hypogonadotropic hypogonadism (HH) and infertility. NR0B1 mutation leads to CAP. Here, we describe a novel pathogenic frameshift variant in NR0B1 associated with congenital adrenal hypoplasia by whole exome sequencing in an Iranian case for the first time. DAX1 encoded by NR0B1 has an essential function during the development of the adrenal cortex and reproductive axes. In CAP patients, laboratory findings show electrolyte disturbances, low androstenedione and low testosterone levels, an increased plasma renin activity, and decreased aldosterone level. More than ten patients with NR0B1 mutations have been reported, but their testosterone levels have been elevated [6]. Our patient showed a high level of testosterone. Premature pubarche, thus, is expected to be observed in our patient in near future of his life. Choosing an appropriate preventive approach for treatment is a crucial step. Of 277 NR0B1 mutations, 108 are frameshift. The c.218_219insACCA as a small insertion leads to a frameshift variant, p.His73GlnfsX41, which is categorized as a pathogenic variant based on ACMG guidelines. As expected, this variant produced a truncated protein with abnormal function. The majority of frameshift variants show their phenotype at earlier ages. There are many reports about congenital adrenal hyperplasia [15, 16], but this case is the first patient with CAP from Iran. Some mutations have a unique pattern of distribution in some populations; e.g., some of the CYP21A2 mutations are common in many cohorts, but some of them are unique [16]. The c.218_219insACCA may have an ancestor in our population, so further studies are recommended to clarify this hypothesis. In conclusion, genetic testing is helpful for differential diagnosis of PAI because variability of phenotypes among patients may lead to a wrong clinical diagnosis. NR0B1 may be a common cause of CAP among Iranian subpopulations. Early diagnosis of this disorder could be helpful in treatment.
  16 in total

1.  Reference ranges still need further clarity.

Authors:  Julian H Barth
Journal:  Ann Clin Biochem       Date:  2009-01       Impact factor: 2.057

2.  NR0B1 Frameshift Mutation in a Boy with Idiopathic Central Precocious Puberty.

Authors:  Hirohito Shima; Shuichi Yatsuga; Akie Nakamura; Shinichiro Sano; Takako Sasaki; Noriyuki Katsumata; Erina Suzuki; Kenichiro Hata; Kazuhiko Nakabayashi; Yukihide Momozawa; Michiaki Kubo; Kohji Okamura; Shigeo Kure; Yoichi Matsubara; Tsutomu Ogata; Satoshi Narumi; Maki Fukami
Journal:  Sex Dev       Date:  2016-09-21       Impact factor: 1.824

3.  An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita.

Authors:  Gokhan Ozisik; Giovanna Mantovani; John C Achermann; Luca Persani; Anna Spada; Jeffrey Weiss; Paolo Beck-Peccoz; J Larry Jameson
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

4.  Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to NR0B1 gene mutations.

Authors:  Zohar Landau; Aaron Hanukoglu; Joseph Sack; Nurit Goldstein; Naomi Weintrob; Alon Eliakim; David Gillis; Michal Sagi; Ruth Shomrat; Elka Bella Kosinovsky; Yair Anikster
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-08       Impact factor: 3.478

5.  The frequency of eight common point mutations in CYP21 gene in Iranian patients with congenital adrenal hyperplasia.

Authors:  Ali Ramazani; Kimia Kahrizi; Maryam Razaghiazar; Nejat Mahdieh; Paul Koppens
Journal:  Iran Biomed J       Date:  2008-01

6.  Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience.

Authors:  Lin Lin; Wen-Xia Gu; Gokhan Ozisik; Wing S To; Catherine J Owen; J Larry Jameson; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

Review 7.  DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease.

Authors:  Jenifer P Suntharalingham; Federica Buonocore; Andrew J Duncan; John C Achermann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 4.690

8.  Late-onset X-linked adrenal hypoplasia (DAX-1, NR0B1): two new adult-onset cases from a single center.

Authors:  Nikolaos Kyriakakis; Tolulope Shonibare; Julie Kyaw-Tun; Julie Lynch; Carlos F Lagos; John C Achermann; Robert D Murray
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

9.  A patient with DAX1  mutation presenting with elevated testosterone in early infancy.

Authors:  Juan Ge; Tang Li
Journal:  World J Pediatr       Date:  2019-03-20       Impact factor: 2.764

10.  The mutational constraint spectrum quantified from variation in 141,456 humans.

Authors:  Konrad J Karczewski; Laurent C Francioli; Grace Tiao; Beryl B Cummings; Jessica Alföldi; Qingbo Wang; Ryan L Collins; Kristen M Laricchia; Andrea Ganna; Daniel P Birnbaum; Laura D Gauthier; Harrison Brand; Matthew Solomonson; Nicholas A Watts; Daniel Rhodes; Moriel Singer-Berk; Eleina M England; Eleanor G Seaby; Jack A Kosmicki; Raymond K Walters; Katherine Tashman; Yossi Farjoun; Eric Banks; Timothy Poterba; Arcturus Wang; Cotton Seed; Nicola Whiffin; Jessica X Chong; Kaitlin E Samocha; Emma Pierce-Hoffman; Zachary Zappala; Anne H O'Donnell-Luria; Eric Vallabh Minikel; Ben Weisburd; Monkol Lek; James S Ware; Christopher Vittal; Irina M Armean; Louis Bergelson; Kristian Cibulskis; Kristen M Connolly; Miguel Covarrubias; Stacey Donnelly; Steven Ferriera; Stacey Gabriel; Jeff Gentry; Namrata Gupta; Thibault Jeandet; Diane Kaplan; Christopher Llanwarne; Ruchi Munshi; Sam Novod; Nikelle Petrillo; David Roazen; Valentin Ruano-Rubio; Andrea Saltzman; Molly Schleicher; Jose Soto; Kathleen Tibbetts; Charlotte Tolonen; Gordon Wade; Michael E Talkowski; Benjamin M Neale; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2020-05-27       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.